Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Sep 29:8:2739-43.
doi: 10.2147/OTT.S90213. eCollection 2015.

Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review

Xiaoyan Li  1 , Hui Yang  1 , Jing Zhao  1 , Hongjun Gao  1
Affiliations
Case Reports

Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review

Xiaoyan Li et al. Onco Targets Ther. .

Abstract

Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase inhibitors (TKIs) is necessary. Spinal cord metastasis of lung cancer is a serious clinical problem. Here, we report a case of lung adenocarcinoma with severe spinal cord metastasis that was successfully treated with a second administration of an EGFR-TKI. Magnetic resonance imaging showed spinal cord metastasis to the cervical vertebrae. The patient received a second administration of an EGFR-TKI (150 mg/day erlotinib). Four months later, we observed the disappearance of the paravertebral tumor and a reduction in the size of pulmonary tumors in both lungs. These results indicate that EGFR-TKI therapy could be a new strategy for the treatment of advanced lung adenocarcinoma with spinal metastasis.

Keywords: NSCLC; compression of spinal cord; erlotinib; target therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Computed tomography scan of the lung before and after 14 months of gefitinib treatment.
Figure 2
Figure 2
Magnetic resonance imaging showing the disappearance of the paraspinal tumor after erlotinib treatment.
Figure 3
Figure 3
Computed tomography scan showing that the lung tumor shrank significantly after erlotinib treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li W, Zhou F, Zhou C. Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. OncoTargets Ther. 2014;7:253–261. - PMC - PubMed
    1. Hata Y, Takai Y, Takahashi H, et al. Complete response of 7 years’ duration after chemoradiotherapy followed by gefitinib in a patient with intramedullary spinal cord metastasis from lung adenocarcinoma. J Thorac Dis. 2013;5(2):E65–E67. - PMC - PubMed
    1. Shah LM, Salzman KL. Imaging of spinal metastatic disease. Int J Surg Oncol. 2011;2011:769753. - PMC - PubMed
    1. Zeng Z, Chen HJ, Yan HH, Yang JJ, Zhang XC, Wu YL. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations. Int J Biol Markers. 2013;28(3):249–258. - PubMed
    1. Cho BC, Im CK, Park MS, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol. 2007;25(18):2528–2533. - PubMed

Publication types